Do you want to read an article? Please log in or register.
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis
Scand J Gastroenterol.
Dignass AU, Siegmund B, Goertz R, Schneidewind G, Fanter L
doi: 10.1080/00365521.
Further Publications
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis
Clin Gastroenterol Hepatol
Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W
doi: 10.1016/j.cgh.2021.07.038
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials
Clin Gastroenterol Hepatol.
Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V
doi: 10.1016/j.cgh.2019.05.019.
Inflammatory Bowel Disease
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
J Crohns Colitis.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W
doi: 10.1093/ecco-jcc/jjz048.
Further Publications
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
Lancet Gastroenterol Hepatol
Croft NM, Faubion WA Jr, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, Mostafa NM, Venetucci M, Finney-Hayward T, Sanchez Gonzalez Y, Bereswill M, Lazar A, Turner D
doi: 10.1016/S2468-1253(21)00142-4
Inflammatory Bowel Disease
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Inflamm Bowel Dis.
Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S
doi: 10.1093/ibd/izy323.
Inflammatory Bowel Disease
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials
J Crohns Colitis.
Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W
doi: 10.1093/ecco-jcc/jjz031.